Scarica l'app Stockscreener
30.50
8.74%
-2.92
Dopo l'orario di chiusura:
30.01
-0.49
-1.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$33.42
Aprire:
$33
Volume 24 ore:
2.59M
Relative Volume:
1.87
Capitalizzazione di mercato:
$1.66B
Reddito:
$11.13M
Utile/perdita netta:
$-81.99M
Rapporto P/E:
-16.96
EPS:
-1.7988
Flusso di cassa netto:
$-68.38M
1 W Prestazione:
+9.32%
1M Prestazione:
+35.86%
6M Prestazione:
+379.56%
1 anno Prestazione:
+138.47%
Intervallo 1D:
$29.41
$33.00
Intervallo di 1 settimana:
$28.98
$36.49
Portata 52W:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
30.50 | 1.66B | 11.13M | -81.99M | -68.38M | -1.7988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? - Yahoo Finance
Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price - Markets Mojo
Capricor Therapeutics (CAPR) Posts US$50 Million H1 Loss Reinforcing Bearish Cash Burn Narrative - simplywall.st
CAPR Stock: Analyst B. Riley Securities Raises Price Target to $ - GuruFocus
Capricor Therapeutics Nears Key Milestones After Earnings Call - TipRanks
Deramiocel Poised to Be First Therapy for DMD's Cardiac and Skeletal Issues - Intellectia AI
Capricor Therapeutics, Inc. (CAPR) Presents at 2026 MDA Clinical & Scientific ConferenceSlideshow - Seeking Alpha
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel (NASDAQ:CAPR) - Seeking Alpha
Capricor Therapeutics (CAPR) Shares Recommended for Purchase Ami - GuruFocus
Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss - marketscreener.com
CAPR Stock: Analyst B. Riley Securities Raises Price Target to $63 | CAPR Stock News - GuruFocus
Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates - Benzinga
CAPR: Piper Sandler Raises Price Target to $58, Reiterates Overw - GuruFocus
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings - AOL.com
Trading the Move, Not the Narrative: (CAPR) Edition - Stock Traders Daily
Why Did Compass Pathways Stock Rocket Higher Today? - AOL.com
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone - MSN
Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial Challenges - GuruFocus
Capricor Therapeutics (CAPR) Advances Duchenne Therapy with FDA Review - GuruFocus
Capricor Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Capricor (CAPR) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Capricor Therapeutics Q4 2025 misses EPS forecasts - Investing.com Nigeria
Capricor Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Capricor Therapeutics Q4 2025 misses EPS forecasts By Investing.com - Investing.com UK
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Capricor Looks Ahead To Deramiocel Approval In DMD - Citeline News & Insights
Capricor Therapeutics falls on Q4 earnings miss By Investing.com - Investing.com Canada
Capricor (CAPR) Focuses on Deramiocel's Approval Amid Financial Growth - GuruFocus
Capricor’s DMD therapy shows heart benefit in phase 3 trial | Tap to know more | Inshorts - Inshorts
Capricor: Q4 Earnings Snapshot - marketscreener.com
Earnings Flash (CAPR) Capricor Therapeutics Posts Q4 Loss $-0.62, vs. FactSet Est of Loss of $-0.55 - marketscreener.com
Fourth quarter and full year 2025 earnings released, Capricor Therapeutics, Inc. outlines - Traders Union
Capricor Therapeutics’ DMD treatment study shows improvement in key heart function measures - MSN
Is It Too Late To Consider Capricor Therapeutics (CAPR) After Strong Multi Year Share Gains? - simplywall.st
Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy - Stocktwits
Capricor Therapeutics’ DMD Treatment Study Shows Improvement In Key Heart Function Measures - Asianet Newsable
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
CAPR Stock In Focus: Capricor Says Phase 3 DMD Trial Shows Cardiac Improvement With Deramiocel - Stocktwits
Capricor Therapeutics (CAPR) Reveals Promising Data from Phase 3 HOPE-3 Trial - GuruFocus
Capricor earnings on deck after FDA resumes deramiocel review By Investing.com - Investing.com Nigeria
Capricor earnings on deck after FDA resumes deramiocel review - Investing.com UK
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy - The Manila Times
Cell therapy for Duchenne slows key eating task decline by 83% - Stock Titan
Capricor: Fourth Quarter Financial Results Overview - Bitget
Capricor Therapeutics (CAPR) Set to Announce Q4 Earnings - GuruFocus
Capricor Therapeutics, Inc. Q4 2025 earnings preview - MSN
Capricor Therapeutics Hits Day High with Strong 9.04% Intraday Surge - Markets Mojo
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):